Literature DB >> 25864844

ShenKang injection suppresses kidney fibrosis and oxidative stress via transforming growth factor-β/Smad3 signalling pathway in vivo and in vitro.

Xiaoxiao Wu1, Yue Guan1, Jiajia Yan1, Meiyou Liu1, Ying Yin1, Jialin Duan1, Guo Wei1, Tianxin Hu1, Yan Weng1, Miaomiao Xi1, Aidong Wen1.   

Abstract

OBJECTIVES: The purpose of this study is to investigate the antifibrosis and antioxidation of ShenKang injection (SKI) in vivo and in vitro and to evaluate potential mechanisms involved in the treatment of chronic kidney disease (CKD).
METHODS: In experimental animal studies, CKD was established by 5/6 nephrectomy (5/6Nx). Serum creatinine (Scr) and blood urea nitrogen (BUN) were determined. Histopathological tests were performed by H&E and Masson trichrome stained. The protein expressions of fibronectin (FN), collagen Ι, α-smooth muscle actin (α-SMA) and transforming growth factor-β (TGF-β) and phosphorylation of Smad3 were measured in 5/6Nx rats. In Human kidney proximal tubular cell line (HK-2) cells, the effects of TGF-β/Smad3 signalling pathway on renal fibrosis and oxidative injury were examined. KEY
FINDINGS: 5/6Nx induced severe renal damages. Treatment of rats with SKI markedly reduced levels of Scr and BUN, alleviated expression of fibrosis-associated signalling molecules and reduced expression of TGF-β and phosphorylated Smad3. Meanwhile, in HK-2 cells, after exposure to TGF-β and H2 O2 , the protein expression of renal fibrosis was significantly increased. The generation of oxidative stress was also elevated. The severity of fibrosis and oxidative damage appears to be reduced after treatment with SKI.
CONCLUSION: SKI inhibits renal fibrosis and oxidative stress through downregulation of TGF-β/Smad3 signalling pathway.
© 2015 Royal Pharmaceutical Society.

Entities:  

Keywords:  ShenKang injection; chronic renal disease; oxidative stress; renal fibrosis

Mesh:

Substances:

Year:  2015        PMID: 25864844     DOI: 10.1111/jphp.12412

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  12 in total

1.  Shenkang Injection for Treating Renal Fibrosis-Metabonomics and Regulation of E3 Ubiquitin Ligase Smurfs on TGF-β/Smads Signal Transduction.

Authors:  Junju Zou; Xiaotao Zhou; Xian Chen; Yuerong Ma; Rong Yu
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

2.  Renoprotective Effect of Formononetin by Suppressing Smad3 Expression in Db/Db Mice.

Authors:  Jiawei Lv; Kai Zhuang; Xiyu Jiang; Heqing Huang; Shijian Quan
Journal:  Diabetes Metab Syndr Obes       Date:  2020-09-28       Impact factor: 3.168

3.  Protective effect and mechanism of Shenkang injection on adenine-induced chronic renal failure in rats.

Authors:  Rongchang Chen; Lijiao Xu; Xu Zhang; Guibo Sun; Wenying Zeng; Xiaobo Sun
Journal:  Acta Cir Bras       Date:  2022-06-01       Impact factor: 1.564

4.  Acetyl-11-keto-β-boswellic acid ameliorates renal interstitial fibrosis via Klotho/TGF-β/Smad signalling pathway.

Authors:  Minna Liu; Tianlong Liu; Peijin Shang; Yikai Zhang; Limin Liu; Ting Liu; Shiren Sun
Journal:  J Cell Mol Med       Date:  2018-07-28       Impact factor: 5.310

5.  Shen-Kang protects against tacrolimus-induced renal injury.

Authors:  Long Ye Zhang; Jian Jin; Kang Luo; Shang Guo Piao; Hai Lan Zheng; Ji Zhe Jin; Sun Woo Lim; Bum Soon Choi; Chul Woo Yang; Can Li
Journal:  Korean J Intern Med       Date:  2018-02-12       Impact factor: 2.884

6.  Shenkang Injection and Its Three Anthraquinones Ameliorates Renal Fibrosis by Simultaneous Targeting IƙB/NF-ƙB and Keap1/Nrf2 Signaling Pathways.

Authors:  Liang-Pu Luo; Ping Suo; Li-Li Ren; Hong-Jiao Liu; Yamei Zhang; Ying-Yong Zhao
Journal:  Front Pharmacol       Date:  2021-12-22       Impact factor: 5.810

Review 7.  The molecular mechanisms of hemodialysis vascular access failure.

Authors:  Akshaar Brahmbhatt; Andrea Remuzzi; Marco Franzoni; Sanjay Misra
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

8.  Does growth differentiation factor 11 protect against myocardial ischaemia/reperfusion injury? A hypothesis.

Authors:  Yongjian Yang; Yi Yang; Xiong Wang; Jin Du; Juanni Hou; Juan Feng; Yue Tian; Lei He; Xiuchuan Li; Haifeng Pei
Journal:  J Int Med Res       Date:  2016-08-25       Impact factor: 1.671

9.  Amelioratory Effects of Testosterone Propionate on Age-related Renal Fibrosis via Suppression of TGF-β1/Smad Signaling and Activation of Nrf2-ARE Signaling.

Authors:  Guoliang Zhang; Yunxiao Kang; Chenming Zhou; Rui Cui; Min Jia; Shen Hu; Xiaoming Ji; Jiayu Yuan; Huixian Cui; Geming Shi
Journal:  Sci Rep       Date:  2018-07-16       Impact factor: 4.379

10.  Efficacy and safety of Shenkang injection in the treatment of chronic renal failure: A protocol of a randomized controlled trial.

Authors:  JuXiang Mei; LingLing Yang; Deqin Wang; HaiXia Wang
Journal:  Medicine (Baltimore)       Date:  2021-12-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.